Granules India gets marketing approval from US FDA for Potassium Chloride Extended Release Tablets

22 Oct 2020 Evaluate

Granules India has received marketing approval from the US Food & Drug Administration (US FDA) for Potassium Chloride Extended Release Tablets USP, 10 mEq (750 mg) and 20 mEq (1500 mg) for the treatment of patients with hypokalemia. Granules’ tablet product is bioequivalent to the reference listed drug (RLD), K-Dur. The drug will be manufactured at the Granules manufacturing facility in Gagillapur, Hyderabad. Granules now have a total of 34 ANDA approvals from the US FDA (32 Final approvals and 2 tentative approvals).

Potassium Chloride Extended Release Tablets USP, 10 mEq & 20 mEq had US generic sales of approximately $204 million for the most recent twelve months ending in Aug 2020.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

544.40 -16.25 (-2.90%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×